Serious adverse reactions in >2% of patients included sepsis, acute kidney injury, urinary tract infection, abdominal pain, and pyrexia. Immune-mediated adverse reactions can occur including pneumonitis, colitis, hepatitis, endocrinopathies, and nephritis.
Dostarlimab
Bezlotoxumab
Tralokinumab
Sacituzumab govitecan
Teprotumumab
Tisotumab vedotin
Ustekinumab
Evolocumab